drospirenone and ethinyl estradiol combination: female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 147740 |
| SCHEMBL ID | 8464101 |
| MeSH ID | M0528511 |
| Synonym |
|---|
| yasmin 28 |
| drospirenone/ethinyl estradiol |
| drospirenone-ethinylestradiol mixt |
| 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-, mixt. with (2's,6r,7r,8r,9s,10r,13s,14s,15s,16s)-3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro(17h-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'h)-furan)-3 |
| ethinylestradiol-drospirenone mixt |
| drospirenone and ethinyl estradiol combination |
| gianvi |
| ee20/drsp |
| dr1021 |
| vestura |
| nikki |
| syeda |
| 164017-31-6 |
| zarah |
| ocella |
| drospirenone; ethinyl estradiol |
| loryna |
| yaz-28 |
| bay 86-5300 |
| SCHEMBL8464101 |
| petibelle |
| DTXSID80936898 |
| 5a,7a-dimethyl-1,1a,5,5a,5b,6,7,7a,8a,9,9a,9b,9c,9d-tetradecahydrospiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-oxolane]-3,5'(4h)-dione--19-norpregna-1(10),2,4-trien-20-yne-3,17-diol (1/1) |
| (1r,2r,4r,10r,11s,14s,15s,16s,18s,19s)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol |
| (4ar,4bs,6as,7s,7as,8as,8bs,8cr,8dr,9ar)-4a,6a-dimethyl-3',4,4a,4b,4',5,6,6a,7a,8,8a,8b,8c,8d,9,9a-hexadecahydro-5'h-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-7,2'-furan]-2,5'(3h)-dione compound with (8r,9s,13s,14s,17r)-17-ethynyl-13 |
| AKOS040751644 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The co- administration of EE had no relevant effect on the pharmacokinetic parameters of 3 mg DRSP." | ( Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women. Blode, H; Kowal, K; Reif, S; Roth, K, 2012) | 0.38 |
| "A moderate pharmacokinetic drug-drug interaction between DRSP and KTZ was demonstrated in this study." | ( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015) | 0.42 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " EE/DRSP 24+4 (24 tablets containing hormones plus 4 containing placebo) features an innovative dosing regimen." | ( [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen]. Bruni Bresciani, V, 2010) | 0.36 |
| " The bleeding patterns of two variants of a flexible dosing regimen designed to manage intracyclic bleeding problems during extended cycles were compared with that of a conventional OC regimen." | ( Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Elliesen, J; Garie, SG; Jensen, JT; Trummer, D, 2012) | 0.38 |
| " The primary regimen [management of intracyclic bleeding (flexible(MIB)) regimen] was an extended dosing regimen that required subjects to initiate 4-day tablet-free intervals after 3 days of breakthrough bleeding/spotting." | ( Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Elliesen, J; Garie, SG; Jensen, JT; Trummer, D, 2012) | 0.38 |
| "A flexible(MIB) dosing regimen of EE 20 mcg/drospirenone 3 mg is associated with good contraceptive efficacy and fewer bleeding/spotting days than the conventional 24/4 regimen." | ( Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Elliesen, J; Garie, SG; Jensen, JT; Trummer, D, 2012) | 0.38 |
| " Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms." | ( Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive. Han, L; Jensen, JT, 2014) | 0.4 |
| "We examine the rationale for flexible extended dosing as well as review the dosing regimen." | ( Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive. Han, L; Jensen, JT, 2014) | 0.4 |
| "Flexible extended dosing of DRSP/EE (3 mg/20 μg) has similar pharmacokinetics and contraceptive efficacy of both conventional and fixed extended regimens." | ( Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive. Han, L; Jensen, JT, 2014) | 0.4 |
| "Although traditionally dosed combined oral contraceptives (COCs) (21 days of active pills, 7 days of inactive pills) have not been demonstrated as superior to placebo for the treatment of premenstrual dysphoria (PMD), some randomized controlled trials (RCTs) indicate that oral contraceptives administered with a shortened or eliminated hormone-free interval are superior to placebo." | ( Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Eisenlohr-Moul, TA; Girdler, SS; Johnson, JL; Rubinow, DR; Schmidt, PJ, 2017) | 0.46 |
| "Fifty-five women with prospectively confirmed PMD completed a three-arm, RCT in which they were randomized to 3 months of placebo (n = 22), intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17), or continuous drospirenone/estradiol (n = 16) following a baseline assessment month." | ( Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Eisenlohr-Moul, TA; Girdler, SS; Johnson, JL; Rubinow, DR; Schmidt, PJ, 2017) | 0.46 |
| "Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type." | ( Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone. Adeyanju, OA; Olatunji, LA, 2019) | 0.51 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (8.80) | 29.6817 |
| 2010's | 103 (82.40) | 24.3611 |
| 2020's | 11 (8.80) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.17) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 51 (39.23%) | 5.53% |
| Reviews | 15 (11.54%) | 6.00% |
| Case Studies | 19 (14.62%) | 4.05% |
| Observational | 5 (3.85%) | 0.25% |
| Other | 40 (30.77%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angeliq Regulatory Post Marketing Surveillance [NCT01064453] | 4,078 participants (Actual) | Observational | 2007-06-30 | Completed | |||
| A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol When Co-administered With GSK2248761 in Healthy Adult Female Subjects [NCT01195974] | Phase 1 | 13 participants (Actual) | Interventional | 2010-09-14 | Terminated(stopped due to In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.) | ||
| The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of Polycystic Ovary Syndrome. [NCT03843736] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-02-21 | Recruiting | ||
| Prospective, Open-label Observational Survey Evaluating Patients Compliance to Administration Regimen During Low Dose Combined Oral Contraceptive Use in Everyday Praxis Data on Oral Contraceptives Compliance - DOC Study [NCT01198444] | 11,884 participants (Actual) | Observational | 2007-12-31 | Completed | |||
| Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS: an Open-label, Non-randomized Controlled Clinical Study [NCT05872425] | 120 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | |||
| Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis [NCT02237131] | Phase 4 | 50 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Low Dose of Aspirin for the Management of Endometriosis-associated Pelvic Pain: a Randomized, Open, Controlled Trial [NCT05156879] | Phase 4 | 220 participants (Anticipated) | Interventional | 2021-12-23 | Recruiting | ||
| A Study in Healthy Female Participants to Investigate the Effect of JNJ-64530440 on the Single-dose of Ethinylestradiol and Drospirenone (Oral Contraceptive), and Midazolam, and the Effect of a High-fat Meal on the Single-dose of JNJ-64530440 [NCT03890341] | Phase 1 | 0 participants (Actual) | Interventional | 2021-06-01 | Withdrawn(stopped due to Stopped due to a strategic decision.) | ||
| A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa [NCT00722800] | Phase 2 | 4 participants (Actual) | Interventional | 2008-10-31 | Terminated(stopped due to Poor recruitment) | ||
| Continuous Versus Cyclical OCP Use in PCOS: A Pilot Study [NCT03819140] | Phase 4 | 60 participants (Actual) | Interventional | 2019-02-01 | Completed | ||
| Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)) [NCT00905684] | 5,446 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms [NCT00927095] | Phase 4 | 67 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Single Center, Double-blind, Randomized Study to Compare the Effect of SH T 00186 D on Follicular Development in a 24-day Regimen Versus a 21-day Regimen in Healthy Female Volunteers [NCT00673686] | Phase 2 | 105 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| An Open-label, Fixed-sequence Cross-over, Two-period, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1358894 on the Pharmacokinetics of a Combination of Ethinylestradiol and Drospirenone in Healthy Female Subjects [NCT05934942] | Phase 1 | 32 participants (Anticipated) | Interventional | 2023-09-08 | Recruiting | ||
| Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone [NCT00468481] | Phase 3 | 385 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Drospirenone and Ethinyl Estradiol Combinations (Yasmin) as Infertility Treatments for Premature Ovarian Failure: a Perspective Follow-up Study. [NCT02757469] | 20 participants (Anticipated) | Interventional | 2016-05-31 | Not yet recruiting | |||
| Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives [NCT00640224] | Phase 4 | 65 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Yasmin Regulatory Post Marketing Surveillance [NCT00923572] | 777 participants (Actual) | Observational | 2007-12-31 | Completed | |||
| A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris [NCT00722761] | Phase 3 | 30 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females [NCT00745901] | Phase 4 | 355 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehyperten [NCT00420342] | Phase 2 | 92 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [NCT01581814] | Phase 3 | 99 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Non-Fasting Conditions. [NCT01182207] | Phase 1 | 33 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants [NCT02027337] | Phase 4 | 200 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| A Multi-center, Open-label, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-cyclodextrin Clathrate and 3 mg Drospire [NCT00569244] | Phase 3 | 223 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [NCT01603745] | Phase 1 | 10 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effects of Odalasvir and AL-335 at Steady-state, Given as Single Agents and in Combination With Simeprevir, on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone [NCT02885454] | Phase 1 | 24 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions. [NCT01182194] | Phase 1 | 32 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study [NCT01109979] | Phase 4 | 24 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Open, Randomized, Parallel Multi-center Comparison of Cycle Control and Safety of the Oral Contraceptive Yasmin 20 in a 24-day Regimen vs. Mercilon for 7 Cycles in 440 Healthy Female Volunteers [NCT00624130] | Phase 3 | 453 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg [NCT00102141] | Phase 3 | 750 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Research on Risk Factors and Comprehensive Intervention Measures of Polycystic Ovary Syndrome Complicated With Mental Diseases Such as Depression and Anxiety [NCT04984070] | 100 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | |||
| [NCT01511822] | Phase 4 | 0 participants | Interventional | Completed | |||
| The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives [NCT00089414] | Phase 2 | 5 participants (Actual) | Interventional | 2004-07-31 | Terminated(stopped due to Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.) | ||
| Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality [NCT01805817] | Phase 4 | 0 participants (Actual) | Interventional | 2012-12-31 | Withdrawn | ||
| Treatment of Polycystic Ovary Syndrome (POS) in Overweight Adolescents [NCT00714233] | Phase 3 | 43 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri [NCT03037944] | Early Phase 1 | 32 participants (Anticipated) | Interventional | 2016-03-01 | Recruiting | ||
| A Mechanistic Examination of Continuous Cycle Oral Contractive Administration in Binge Eating [NCT04278755] | Phase 2 | 8 participants (Actual) | Interventional | 2020-09-24 | Terminated(stopped due to Halted prematurely due to COVID-19-related enrollment challenges.) | ||
| The Oral Contraceptive Pill for Premenstrual Worsening of Depression. [NCT00633360] | 32 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midaz [NCT03111511] | Phase 1 | 18 participants (Actual) | Interventional | 2017-03-27 | Completed | ||
| A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of Multiple Doses of BMS-986278 on the Pharmacokinetics of Combined Oral Contraceptives (Drospirenone/Ethinyl Estradiol) in Healthy Female Participants [NCT05985590] | Phase 1 | 36 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Drug-drug Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone [NCT03126097] | Phase 1 | 18 participants (Actual) | Interventional | 2017-04-13 | Terminated(stopped due to Study stopping rules were met.) | ||
| The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study [NCT05135013] | 200 participants (Anticipated) | Observational | 2021-11-16 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||